Literature DB >> 19602323

The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation.

Milton Hamblin1, Lin Chang, Jifeng Zhang, Y Eugene Chen.   

Abstract

Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily. It is expressed in adipocytes, immune cells, and cardiovascular cells that include cardiomyocytes, endothelial cells, and smooth muscle cells. PPARgamma plays a role in regulating cellular anti-inflammatory responses and is a mediator of insulin sensitization induced by thiazolidinediones, which also can reduce elevated blood pressure both clinically and experimentally. As a result, research regarding the role of PPARgamma in blood pressure homeostasis is ongoing. Recent studies have demonstrated that increases or decreases in blood pressure phenotype may be PPARgamma-dependent and involve a number of different signaling pathways. Furthermore, studies using PPARgamma mutant transgenic and knockout animal models provide further evidence regarding a role for endothelial-cell and vascular smooth muscle-cell PPARgamma in blood pressure regulation. However, there is a need for further research regarding PPARgamma--mediated mechanisms involved in maintaining physiologic control of blood pressure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602323     DOI: 10.1007/s11906-009-0041-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  50 in total

Review 1.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Authors:  Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn
Journal:  Circulation       Date:  2003-12-09       Impact factor: 29.690

2.  Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.

Authors:  Guoliang Ding; Mingui Fu; Qianhong Qin; William Lewis; Ha Won Kim; Tohru Fukai; Methode Bacanamwo; Yuqing Eugene Chen; Michael D Schneider; David J Mangelsdorf; Ronald M Evans; Qinglin Yang
Journal:  Cardiovasc Res       Date:  2007-07-04       Impact factor: 10.787

Review 3.  Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.

Authors:  Panteleimon A Sarafidis; Anastasios N Lasaridis
Journal:  Am J Hypertens       Date:  2006-06       Impact factor: 2.689

4.  A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

Authors:  Martin St John Sutton; Marc Rendell; Paresh Dandona; Jo F Dole; Karen Murphy; Rita Patwardhan; Jai Patel; Martin Freed
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

5.  Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.

Authors:  Ikuyo Imayama; Toshihiro Ichiki; Keita Inanaga; Hideki Ohtsubo; Kae Fukuyama; Hiroki Ono; Yasuko Hashiguchi; Kenji Sunagawa
Journal:  Cardiovasc Res       Date:  2006-07-21       Impact factor: 10.787

6.  The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Authors:  T M Willson; J E Cobb; D J Cowan; R W Wiethe; I D Correa; S R Prakash; K D Beck; L B Moore; S A Kliewer; J M Lehmann
Journal:  J Med Chem       Date:  1996-02-02       Impact factor: 7.446

7.  Impaired expression of PPAR gamma protein contributes to the exaggerated growth of vascular smooth muscle cells in spontaneously hypertensive rats.

Authors:  Chen Xiong; Yongshan Mou; Jifeng Zhang; Mingui Fu; Yuqing E Chen; Mukaila A Akinbami; Taixing Cui
Journal:  Life Sci       Date:  2005-06-20       Impact factor: 5.037

8.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

9.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  9 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

2.  Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation.

Authors:  Zhe Meng; Xin-hui Yu; Jun Chen; Ling Li; Sheng Li
Journal:  Acta Pharmacol Sin       Date:  2014-08-18       Impact factor: 6.150

3.  Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation.

Authors:  Milton Hamblin; Lin Chang; Hengmin Zhang; Kun Yang; Jifeng Zhang; Y Eugene Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-18       Impact factor: 8.311

4.  Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease.

Authors:  K L Raphael; K A Strait; P K Stricklett; B C Baird; K Piontek; G G Germino; D E Kohan
Journal:  Am J Nephrol       Date:  2009-09-24       Impact factor: 3.754

Review 5.  Oxidative stress and vascular function: implications for pharmacologic treatments.

Authors:  Antje R Weseler; Aalt Bast
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

6.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

Review 7.  PPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic Syndrome.

Authors:  You-Lin Tain; Chien-Ning Hsu; Julie Y H Chan
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

8.  Early Postweaning Treatment with Dimethyl Fumarate Prevents Prenatal Dexamethasone- and Postnatal High-Fat Diet-Induced Programmed Hypertension in Male Rat Offspring.

Authors:  Yu-Ju Lin; I-Chun Lin; Hong-Ren Yu; Jiunn-Ming Sheen; Li-Tung Huang; You-Lin Tain
Journal:  Oxid Med Cell Longev       Date:  2018-02-15       Impact factor: 6.543

9.  Maternal Melatonin Therapy Attenuated Maternal High-Fructose Combined with Post-Weaning High-Salt Diets-Induced Hypertension in Adult Male Rat Offspring.

Authors:  You-Lin Tain; Steve Leu; Wei-Chia Lee; Kay L H Wu; Julie Y H Chan
Journal:  Molecules       Date:  2018-04-11       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.